Latest News and Press Releases
Want to stay updated on the latest news?
-
Alumis Reports Year End 2024 Financial Results and Highlights Recent Achievements
-
Phase 1 Data at ACTRIMS Forum 2025 supports potential of A-005 as first-in-class CNS-penetrant TYK2 Inhibitor for neuroinflammatory diseases